Efficacy and Safety Study on Low Molecular Heparin in the Prevention for Venous Thromboembolism Prophylaxis after Spontaneous Intracerebral Hemorrhage

Jie NI,Jian QIAN,Lu-Na WANG,Fang WANG,Du-Juan SHA
DOI: https://doi.org/10.3969/j.issn.1673-5765.2018.06.006
2018-01-01
Abstract:Objective To assess the efficacy of low molecular weight heparin (LMWH) for deep vein thrombosis (DVT) in patients with spontaneous intracerebral hemorrhage (sICH) during early stage. Methods One hundred and four patients with sICH were enrolled in our study: LMWH group (n=51) and control group (n=53). The patients of LMWH group were injected hypodermically with LMWH (Enoxaparin Sodium Injection, 0.4 ml/d) from day 4th to day 10th after admittance. While the patients in control group received intermittent pneumatic compression (IPC). The LPA and the anticoagulant factor Xa level were detected on admission day and the treatment of low molecular heparin for the 7th day in all patients, and whether the patient had bleeding signs were observed. Results No hematoma enlargement were observed in both groups. After treatment, the serum level of LPA were significantly lower in LMWH group than that of the control group (11.74±5.30 ng/ml vs 26.81±5.12 ng/ml, P<0.05). The level of anti-Xa were significantly higher in LMWH group than that of the control group (25.96±7.97 ng/mlvs 8.06±1.32 ng/ml,P<0.05). Conclusion The hospitalized patients with acute sICH were the crowd with high risk of DVT. LMWH in doses of 0.4 ml once daily during acute phase in patients with sICH is safe and efficient.
What problem does this paper attempt to address?